-
HKU and SIIDB Collaborate on Drug Development for Infectious Diseases
•
The Department of Microbiology at the University of Hong Kong (HKU) and the Shanghai Institute of Infectious Disease and Biosecurity (SIIDB) have entered into a Memorandum of Understanding (MoU) to collaborate on drug development. This strategic partnership aims to establish the United Research Center of Innovative Drugs for Major Infectious…
-
Dizal Pharmaceutical Presents Updates on DZD8586 and Golidocitinib at ASH Annual Meeting
•
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) provided updates on the clinical development of its drug candidates, DZD8586 and the JAK1 inhibitor golidocitinib (DZD4205), at the 65th American Society of Hematology (ASH) annual meeting. The event showcased the latest findings from the company’s research and development efforts in the field…
-
XtalPi Inc. and CK Life Sciences Expand Partnership to Develop AI-Powered Cancer Diagnostics
•
Sino-US artificial intelligence (AI) firm XtalPi Inc. has announced a strategic partnership agreement with China-based CK Life Sciences (HKG: 0775). The collaboration aims to leverage AI and clinical diagnosis data, including biomarker information from cancer patients and healthy populations, to develop molecular diagnostic models that predict cancer prognosis risk based…
-
Zhejiang Huahai Pharmaceutical’s HB0052 Receives US FDA IND Approval for Solid Tumors
•
IntroductionZhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521), a China-based pharmaceutical company, has announced that it has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for its injectable drug candidate, HB0052. The drug will initially be assessed in general advanced solid tumors, marking a significant…
-
BeiGene’s ZW25 on Track for Priority Review for Cholangiocarcinoma Treatment by CDE
•
The Center for Drug Evaluation (CDE) website has indicated that BeiGene’s (NASDAQ: BGNE) ZW25 (zanidatamab) is set to receive priority review status for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma in patients with high HER2 expression who have previously received systemic treatment. This priority review status is a…
-
Innovent Biologics Presents Positive Clinical Results for Efdamrofusp Alfa and IBI324 at AAO
•
Innovent Biologics, Inc. (HKG: 1801), a China-based biopharmaceutical company, has published the latest clinical results for its two drug candidates, efdamrofusp alfa (IBI302) and IBI324, at the American Association of Ophthalmology (AAO) meeting. IBI302 is a recombinant fully human anti-VEGF and anti-complement bispecific fusion protein, while IBI324 is a bispecific…
-
CSPC Pharmaceutical Group Gets NMPA Approval for SYS6011 Biologic Drug Clinical Study
•
CSPC Pharmaceutical Group Ltd (HKG: 1093), a China-based pharmaceutical company, has announced that it has received approval from China’s National Medical Products Administration (NMPA) to conduct a clinical study for its Category 1 biologic drug candidate, SYS6011. The study will be focused on general solid tumors, marking a significant step…
-
Bayer Extends Collaboration with Broad Institute to 2028 for Oncology Drug Targets and Therapies
•
Germany’s Bayer (NYSE: ETR) has announced the extension of its 2013 collaboration agreement with the US-based research center, the Broad Institute, until 2028. The partnership focuses on identifying new drug targets in oncology and developing innovative cancer therapies. The financial details of the extended agreement have not been disclosed. Combining…
